Orthobiologics Market

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $4,850	181 Pages	Fortune Business Insights Pvt. Ltd.	October, 2024	FOB19260639

Best Price Guarantee
Price	from $4,850
Length	181 Pages
Publisher	Fortune Business Insights Pvt. Ltd.
Published Date	October, 2024
SKU	FOB19260639

Orthobiologics Market

Growth Factors of Orthobiologics Market

The orthobiologics market size was valued at USD 8.77 billion in 2023, and the market is now projected to grow from 9.22 billion in 2024 to USD 14.42 billion by 2032, exhibiting a CAGR of 5.7% during the forecast period of 2024-2032.

COVID 19 affected orthobiologics market worldwide affecting supply chain and Elective surgeries caused by lock down measures. Due to the COVID-19 breakout, many hospitals shifted their focus to treat COVID patients and a large number of elective surgeries including orthopaedic, orthobiologics got delayed, thus reducing the market of orthobiologics products. However, there has been a boost in the sector after the COVID increased concentration on the recovery of the patients after admissions. Further, growth in the healthcare technology front such as telemedicine and remote patient monitoring during covid has paved way for orthobiologics to come up with new ideas and innovations when adapting to the new future.

The orthobiologics market has experienced few key characteristics; some of the advancements include regenerative medicine procedures like stem cell therapy and platelet-rich plasma (PRP) therapy. High demands for minimally invasive surgery have lead to the creation of new delivery methods for orthobiologics. Not only has specialization in biomaterials improved the effectiveness of treatments, but this knowledge leads to better outcomes. While technology like 3D printing and the application of artificial intelligence is also influencing the form of product design and custom treatment options. In order to sum, these trends depict better patient centric approach and improved recovery solutions. Thus, all the above mentioned factors are contributing towards the veterinary diagnostics market growth.

There are several market drivers contributing to the growth of orthobiologics market today these include increased incidence of musculoskeletal disorder, increased population and advances in technology. Progress made in the use of stem cells, tissue engineering and other applications improve the prospects for development of orthobiologics. Furthermore, increasing demand for minimally invasive products by patients and physicians experience is also driving the market. Higher levels of research and development spending by global pharmaceuticals and biotechnology industries are also enhancing the pace of innovation in this segment, and the subsequent launch of value-added products and therapies.

Comprehensive Analysis Orthobiologics Market

For segmentation purpose, the orthobiologics market has been divided based on product type, application and end use. Some of the most important products are: joint therapies such as visco-supplements that down regulates joint pain; growth factors for bone healing; DBM; synthetic bone grafts; and cellular allograft for instance. In terms of applications, it operates in spinal fusion, maxillo facial / dental, soft tissue repair, reconstructive/ fracture surgeries and many others. The targets are hospitals and ambulatory surgical centers (ASCs), reprocessing specialty clinics, and other user facilities that demonstrate a wide range of orthobiologics applications to multiple patient populations.

North America has the strongest market for orthobiologics due to social factors such as; well-developed health system, high health care costs and increasing frail of geriatric population who are prone to orthobiologics requirement diseases. The region has excellent R&D investments to support growth in regenerative medicine and orthobiologics products. Moreover, the strong growth of key market players, trump card medical facilities raises the acceptance levels of new technological treatments. Sports injuries are more and more common and there is a higher demand for using orthobiologics as an endovenous treatment which also explain why North America leads the orthobiologics market in the world.

Key players in this sector include Medtronic (Ireland), Zimmer Biomet (U.S.), DePuy Synthes (Johnson & Johnson Services, Inc.) (U.S.), Stryker (U.S.), Anika Therapeutics, Inc. (U.S.), SeaSpine (U.S.), Bioventus (U.S.), RTI Surgical (U.S.), MTF Biologics (U.S.)

One of the most observed trends in the orthobiologics market in 2023 is an increased utilization of various highly-developed cellular therapies with Particular Focus on Stem Cells. The use of these therapies in furthering recovery in orthopedic operations is gradually gaining acceptance. Business are paying attention on creation of products containing adipose-derived stem cells and bone marrow aspirate for better regenerative results in conditions linked with osteoarthritis and tendon disorders. This transition to molecular biology based medicine as a result of developing bio-processing and cellular technologies is however an indication of an increasing focus on the use of more efficient treatment protocols in orthobiologics.

Segmentation Table

ATTRIBUTE DETAILS

Study Period 2019-2032

Base Year 2023

Estimated Year 2024

Forecast Period 2024-2032

Historical Period 2019-2022

Growth Rate CAGR of 5.7% from 2024-2032

Unit Value (USD billion)

Segmentation

By Product Type

Viscosupplements

Bone Growth Factors

Demineralized Bone Matrix (DBM)

Synthetic Bone Substitutes

Cellular Allograft

Others

By Application

Spinal Fusion

Maxillofacial & Dental

Soft Tissue Repair

Reconstructive & Fracture Surgery

Others

By End-user

Hospitals & ASCs

Specialty Clinics

Others

By Geography

North America (By Product Type, By Application, By End-user, and By Country)

U.S. (By Application)
Canada (By Application)

Europe (By Product Type, By Application, By End-user, and By Country/Sub-region)

Germany (By Application)
U.K. (By Application)
France (By Application)
Italy (By Application)
Scandinavia (By Application)
Rest of Europe (By Application)

Asia Pacific (By Product Type, By Application, By End-user, and By Country/Sub-region)

China (By Application)
India (By Application
Japan (By Application)
Australia (By Application)
Southeast Asia (By Application)
Rest of Asia Pacific (By Application)

Latin America (By Product Type, By Application, By End-user, and By Country/Sub-region)

Brazil (By Application)
Mexico (By Application)
Rest of Latin America (By Application)

Middle East & Africa (By Product Type, By Application, By End-user, and By Country/Sub-region)

South Africa (By Application)
GCC (By Application)
Rest of Middle East & Africa (By Application)

1. Introduction: 1.1. Research Scope; 1.2. Market Segmentation; 1.3. Research Methodology; 1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics: 3.1. Market Drivers; 3.2. Market Restraints; 3.3. Market Opportunities; 3.4. Market Trends
4. Key Insights: 4.1. Epidemiology of Clinical Indications; 4.2. Regulatory Scenario for Key Countries; 4.3. New Product Launches; 4.4. Key Industry Developments (Mergers, Acquisitions, and Partnership); 4.5. Impact of COVID-19 on the Market
5. Global Orthobiologics Market Analysis, Insights and Forecast, 2019-2032: 5.1. Market Analysis, Insights and Forecast – By Product Type; 5.1.1. Viscosupplements; 5.1.2. Bone Growth Factors; 5.1.3. Demineralized Bone Matrix (DBM); 5.1.4. Synthetic Bone Substitutes; 5.1.5. Cellular Allograft; 5.1.6. Allografts; 5.1.7. Others; 5.2. Market Analysis, Insights and Forecast – By Application; 5.2.1. Spinal Fusion; 5.2.2. Maxillofacial & Dental; 5.2.3. Soft Tissue Repair; 5.2.4. Reconstructive & Fracture Surgery; 5.2.5. Others; 5.3. Market Analysis, Insights and Forecast – By End-user; 5.3.1. Hospitals & ASCs; 5.3.2. Specialty Clinics; 5.3.3. Others; 5.4. Market Analysis, Insights and Forecast – By Region; 5.4.1. North America; 5.4.2. Europe; 5.4.3. Asia Pacific; 5.4.4. Latin America; 5.4.5. Middle East & Africa
6. North America Orthobiologics Market Analysis, Insights and Forecast, 2019-2032: 6.1. Market Analysis, Insights and Forecast – By Product Type; 6.1.1. Viscosupplements; 6.1.2. Bone Growth Factors; 6.1.3. Demineralized Bone Matrix (DBM); 6.1.4. Synthetic Bone Substitutes; 6.1.5. Cellular Allograft; 6.1.6. Allografts; 6.1.7. Others; 6.2. Market Analysis, Insights and Forecast – By Application; 6.2.1. Spinal Fusion; 6.2.2. Maxillofacial & Dental; 6.2.3. Soft Tissue Repair; 6.2.4. Reconstructive & Fracture Surgery; 6.2.5. Others; 6.3. Market Analysis, Insights and Forecast – By End-user; 6.3.1. Hospitals & ASCs; 6.3.2. Specialty Clinics; 6.3.3. Others; 6.4. Market Analysis, Insights and Forecast – By Country; 6.4.1. U.S.; 6.4.1.1. By Application; 6.4.2. Canada; 6.4.2.1. By Application
7. Europe Orthobiologics Market Analysis, Insights and Forecast, 2019-2032: 7.1. Market Analysis, Insights and Forecast – By Product Type; 7.1.1. Viscosupplements; 7.1.2. Bone Growth Factors; 7.1.3. Demineralized Bone Matrix (DBM); 7.1.4. Synthetic Bone Substitutes; 7.1.5. Cellular Allograft; 7.1.6. Allografts; 7.1.7. Others; 7.2. Market Analysis, Insights and Forecast – By Application; 7.2.1. Spinal Fusion; 7.2.2. Maxillofacial & Dental; 7.2.3. Soft Tissue Repair; 7.2.4. Reconstructive & Fracture Surgery; 7.2.5. Others; 7.3. Market Analysis, Insights and Forecast – By End-user; 7.3.1. Hospitals & ASCs; 7.3.2. Specialty Clinics; 7.3.3. Others; 7.4. Market Analysis, Insights and Forecast – By Country/ Sub-region; 7.4.1. Germany; 7.4.1.1. By Application; 7.4.2. U.K.; 7.4.2.1. By Application; 7.4.3. France; 7.4.3.1. By Application; 7.4.4. Italy; 7.4.4.1. By Application; 7.4.5. Spain; 7.4.5.1. By Application; 7.4.6. Scandinavia; 7.4.6.1. By Application; 7.4.7. Rest of Europe; 7.4.7.1. By Application
8. Asia Pacific Orthobiologics Market Analysis, Insights and Forecast, 2019-2032: 8.1. Market Analysis, Insights and Forecast – By Product Type; 8.1.1. Viscosupplements; 8.1.2. Bone Growth Factors; 8.1.3. Demineralized Bone Matrix (DBM); 8.1.4. Synthetic Bone Substitutes; 8.1.5. Cellular Allograft; 8.1.6. Allografts; 8.1.7. Others; 8.2. Market Analysis, Insights and Forecast – By Application; 8.2.1. Spinal Fusion; 8.2.2. Maxillofacial & Dental; 8.2.3. Soft Tissue Repair; 8.2.4. Reconstructive & Fracture Surgery; 8.2.5. Others; 8.3. Market Analysis, Insights and Forecast – By End-user; 8.3.1. Hospitals & ASCs; 8.3.2. Specialty Clinics; 8.3.3. Others; 8.4. Market Analysis, Insights and Forecast – By Country/ Sub-region; 8.4.1. China; 8.4.1.1. By Application; 8.4.2. India; 8.4.2.1. By Application; 8.4.3. Japan; 8.4.3.1. By Application; 8.4.4. Australia; 8.4.4.1. By Application; 8.4.5. Southeast Asia; 8.4.5.1. By Application; 8.4.6. Rest of Asia Pacific; 8.4.6.1. By Application
9. Latin America Orthobiologics Market Analysis, Insights and Forecast, 2019-2032: 9.1. Market Analysis, Insights and Forecast – By Product Type; 9.1.1. Viscosupplements; 9.1.2. Bone Growth Factors; 9.1.3. Demineralized Bone Matrix (DBM); 9.1.4. Synthetic Bone Substitutes; 9.1.5. Cellular Allograft; 9.1.6. Allografts; 9.1.7. Others; 9.2. Market Analysis, Insights and Forecast – By Application; 9.2.1. Spinal Fusion; 9.2.2. Maxillofacial & Dental; 9.2.3. Soft Tissue Repair; 9.2.4. Reconstructive & Fracture Surgery; 9.2.5. Others; 9.3. Market Analysis, Insights and Forecast – By End-user; 9.3.1. Hospitals & ASCs; 9.3.2. Specialty Clinics; 9.3.3. Others; 9.4. Market Analysis, Insights and Forecast – By Country/ Sub-region; 9.4.1. Brazil; 9.4.1.1. By Application; 9.4.2. Mexico; 9.4.2.1. By Application; 9.4.3. Rest of Latin America; 9.4.3.1. By Application
10. Middle East & Africa Orthobiologics Market Analysis, Insights and Forecast, 2019-2032: 10.1. Market Analysis, Insights and Forecast – By Product Type; 10.1.1. Viscosupplements; 10.1.2. Bone Growth Factors; 10.1.3. Demineralized Bone Matrix (DBM); 10.1.4. Synthetic Bone Substitutes; 10.1.5. Cellular Allograft; 10.1.6. Allografts; 10.1.7. Others; 10.2. Market Analysis, Insights and Forecast – By Application; 10.2.1. Spinal Fusion; 10.2.2. Maxillofacial & Dental; 10.2.3. Soft Tissue Repair; 10.2.4. Reconstructive & Fracture Surgery; 10.2.5. Others; 10.3. Market Analysis, Insights and Forecast – By End-user; 10.3.1. Hospitals & ASCs; 10.3.2. Specialty Clinics; 10.3.3. Others; 10.4. Market Analysis, Insights and Forecast – By Country/ Sub-region; 10.4.1. South Africa; 10.4.1.1. By Application; 10.4.2. GCC; 10.4.2.1. By Application; 10.4.3. Rest of Middle East & Africa; 10.4.3.1. By Application
11. Competitive Analysis: 11.1. Global Market Share Analysis (2023); 11.2. Company Profiles; 11.2.1. Medtronic; 11.2.1.1. Overview; 11.2.1.2. Products; 11.2.1.3. SWOT Analysis; 11.2.1.4. Recent Developments; 11.2.1.5. Strategies; 11.2.1.6. Financials (Based on Availability); 11.2.2. Zimmer Biomet; 11.2.2.1. Overview; 11.2.2.2. Products; 11.2.2.3. SWOT Analysis; 11.2.2.4. Recent Developments; 11.2.2.5. Strategies; 11.2.2.6. Financials (Based on Availability); 11.2.3. DePuy Synthes (Johnson & Johnson Services, Inc.); 11.2.3.1. Overview; 11.2.3.2. Products; 11.2.3.3. SWOT Analysis; 11.2.3.4. Recent Developments; 11.2.3.5. Strategies; 11.2.3.6. Financials (Based on Availability); 11.2.4. Stryker; 11.2.4.1. Overview; 11.2.4.2. Products; 11.2.4.3. SWOT Analysis; 11.2.4.4. Recent Developments; 11.2.4.5. Strategies; 11.2.4.6. Financials (Based on Availability); 11.2.5. Anika Therapeutics, Inc.; 11.2.5.1. Overview; 11.2.5.2. Products; 11.2.5.3. SWOT Analysis; 11.2.5.4. Recent Developments; 11.2.5.5. Strategies; 11.2.5.6. Financials (Based on Availability); 11.2.6. SeaSpine; 11.2.6.1. Overview; 11.2.6.2. Products; 11.2.6.3. SWOT Analysis; 11.2.6.4. Recent Developments; 11.2.6.5. Strategies; 11.2.6.6. Financials (Based on Availability); 11.2.7. Bioventus; 11.2.7.1. Overview; 11.2.7.2. Products; 11.2.7.3. SWOT Analysis; 11.2.7.4. Recent Developments; 11.2.7.5. Strategies; 11.2.7.6. Financials (Based on Availability); 11.2.8. RTI Surgical; 11.2.8.1. Overview; 11.2.8.2. Products; 11.2.8.3. SWOT Analysis; 11.2.8.4. Recent Developments; 11.2.8.5. Strategies; 11.2.8.6. Financials (Based on Availability); 11.2.9. MTF Biologics; 11.2.9.1. Overview; 11.2.9.2. Products; 11.2.9.3. SWOT Analysis; 11.2.9.4. Recent Developments; 11.2.9.5. Strategies; 11.2.9.6. Financials (Based on Availability); 11.2.10. Arthrex, Inc.; 11.2.10.1. Overview; 11.2.10.2. Products; 11.2.10.3. SWOT Analysis; 11.2.10.4. Recent Developments; 11.2.10.5. Strategies; 11.2.10.6. Financials (Based on Availability); 11.2.11. Smith & Nephew; 11.2.11.1. Overview; 11.2.11.2. Products; 11.2.11.3. SWOT Analysis; 11.2.11.4. Recent Developments; 11.2.11.5. Strategies; 11.2.11.6. Financials (Based on Availability)